Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Cellular Biomedicine Group Inc (NASDAQ:CBMG)

Delayed Data
As of 4:00pm ET
 +0.29 / +1.29%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Cellular Biomedicine Group, Inc. is a biomedicine company. It engages in the development of new treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. The company's developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. It operates in two segments: Biomedicine and Consulting. The Biomedicine segment is in development stage, conducting research and development activities to commercialize stem cell and immune cell therapeutics, related tools and products. The Consulting segment provides services to foreign and domestic companies seeking access to the U.S. capital markets. Cellular Biomedicine Group was founded in 2009 and is headquartered in Palo Alto, CA.

Contact Information

Cellular Biomedicine Group, Inc.
530 University Avenue
Palo Alto California 94301
P:(650) 566-5064
Investor Relations:



Mutual fund holders4.67%
Other institutional3.75%
Individual stakeholders16.18%

Top Executives

Wen Tao LiuChairman & President-North America
Wei CaoChief Executive Officer & Director
Richard L. WangChief Operating Officer
Bizuo LiuChief Financial Officer & Secretary
Maxwell WangDirector-Medical Research